Hyperbaric oxygen therapy for promoting fracture healing and treating fracture non-union

Citation: Bennett MH, Stanford R, Turner R. Hyperbaric oxygen therapy for promoting fracture healing and treating fracture non-union (Cochrane Review). In: The Cochrane Library (Issue 4, 2004). Chichester, UK: John Wiley & Sons, Ltd.

Background

Hyperbaric oxygen therapy (HBOT) consists of intermittently administering 100% oxygen at pressures greater than one atmosphere absolute (ATA) in a pressure vessel. This technology has been used to treat a variety of diseases and has been described as helping patients who have delayed healing or established non-union of bony fractures.

 Objectives

The aim of this review was to assess the evidence for the benefit of hyperbaric oxygen treatment (HBOT) for the treatment of delayed bony healing and established non-union of bony fractures.

 Search strategy

We searched the Cochrane Musculoskeletal Injuries Group trials register (to January week 3, 2004), the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 4, 2003), MEDLINE (OVID 1966 to January week 3, 2004), CINAHL (OVID 1982 to January week 3, 2004), EMBASE (OVID 1980 to February 2004), the locally developed Database of Randomised Controlled Trials in Hyperbaric Medicine (available at www.hboevidence.com) from inception to March 2004, and reference lists of articles.

 Selection criteria

We aimed to include all randomised controlled trials that compared the effect of HBOT with no HBOT (no treatment or sham).

 Data collection & analysis

Two authors using standardised forms attempted to extract data independently.

 Main results

No trials met the inclusion criteria. We excluded one trial that compared HBOT with no treatment because no clinical outcomes were reported.

 Reviewers' conclusions

This systematic review failed to locate any relevant clinical evidence to support or refute the effectiveness of HBOT for the management of delayed union or established non-union of bony fractures. Good quality clinical trials are needed to define the role, if any, of HBOT in the treatment of these injuries.